GLPwatch
Wegovy for Parkinson's disease
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCWegovy (semaglutide) is not FDA-approved for Parkinson's disease, and any use for this condition is off-label or investigational. Research in animal models suggests semaglutide may have neuroprotective effects and reduce markers linked to Parkinson's disease, but these findings have not been confirmed in human trials.
AI summary of the sources below.
| Drug | Wegovy (semaglutide) |
|---|---|
| Condition | Parkinson's disease |
| Approval status | Investigational / off-label |
| Research papers | 11 |
Wegovy is not FDA-approved for parkinson's disease; the research below reflects investigational or off-label study only.
Research on semaglutide for parkinson's disease (11)
- Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease.
- Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model.
- Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues-Liraglutide and Semaglutide.
- DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce <i>α</i>-Synuclein Levels in the 6-OHDA Parkinson's Disease Rat Model.
- Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress.
- The GLP1R Agonist Semaglutide Inhibits Reactive Astrocytes and Enhances the Efficacy of Neural Stem Cell Transplantation Therapy in Parkinson's Disease Mice.
- Neuroprotective effects of semaglutide and metformin against rotenone-induced neurobehavioral changes in male diabetic rats.
- Neuroprotective and cognitive benefits of Semaglutide: Insights into the underlying molecular mechanisms.
- Semaglutide and the pathogenesis of progressive neurodegenerative disease: the central role of mitochondria.
- Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide.
- Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson's disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study.